dc.creator | Hatzakis, A. | en |
dc.creator | Van Damme, P. | en |
dc.creator | Alcorn, K. | en |
dc.creator | Gore, C. | en |
dc.creator | Benazzouz, M. | en |
dc.creator | Berkane, S. | en |
dc.creator | Buti, M. | en |
dc.creator | Carballo, M. | en |
dc.creator | Cortes Martins, H. | en |
dc.creator | Deuffic-Burban, S. | en |
dc.creator | Dominguez, A. | en |
dc.creator | Donoghoe, M. | en |
dc.creator | Elzouki, A. N. | en |
dc.creator | Ben-Alaya Bouafif, N. | en |
dc.creator | Esmat, G. | en |
dc.creator | Esteban, R. | en |
dc.creator | Fabri, M. | en |
dc.creator | Fenton, K. | en |
dc.creator | Goldberg, D. | en |
dc.creator | Goulis, I. | en |
dc.creator | Hadjichristodoulou, T. | en |
dc.creator | Hatzigeorgiou, T. | en |
dc.creator | Hamouda, O. | en |
dc.creator | Hasurdjiev, S. | en |
dc.creator | Hughes, S. | en |
dc.creator | Kautz, A. | en |
dc.creator | Malik, M. | en |
dc.creator | Manolakopoulos, S. | en |
dc.creator | Matičič, M. | en |
dc.creator | Papatheodoridis, G. | en |
dc.creator | Peck, R. | en |
dc.creator | Peterle, A. | en |
dc.creator | Potamitis, G. | en |
dc.creator | Prati, D. | en |
dc.creator | Roudot-Thoraval, F. | en |
dc.creator | Reic, T. | en |
dc.creator | Sharara, A. | en |
dc.creator | Shennak, M. | en |
dc.creator | Shiha, G. | en |
dc.creator | Shouval, D. | en |
dc.creator | Sočan, M. | en |
dc.creator | Thomas, H. | en |
dc.creator | Thursz, M. | en |
dc.creator | Tosti, M. | en |
dc.creator | Trépo, C. | en |
dc.creator | Vince, A. | en |
dc.creator | Vounou, E. | en |
dc.creator | Wiessing, L. | en |
dc.creator | Manns, M. | en |
dc.date.accessioned | 2015-11-23T10:29:58Z | |
dc.date.available | 2015-11-23T10:29:58Z | |
dc.date.issued | 2013 | |
dc.identifier | 10.1111/jvh.12120 | |
dc.identifier.issn | 13520504 | |
dc.identifier.uri | http://hdl.handle.net/11615/28449 | |
dc.description.abstract | The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk groups and migrants, because of a lack of reliable epidemiological data, suggesting the need for better and targeted surveillance for public health gains. In many countries, the burden of chronic liver disease due to hepatitis B and C is increasing due to ageing of unvaccinated populations and migration, and a probable increase in drug injecting. Targeted vaccination strategies for hepatitis B virus (HBV) among risk groups and harm reduction interventions at adequate scale and coverage for injecting drug users are needed. Transmission of HBV and hepatitis C virus (HCV) in healthcare settings and a higher prevalence of HBV and HCV among recipients of blood and blood products in the Balkan and North African countries highlight the need to implement and monitor universal precautions in these settings and use voluntary, nonremunerated, repeat donors. Progress in drug discovery has improved outcomes of treatment for both HBV and HCV, although access is limited by the high costs of these drugs and resources available for health care. Egypt, with the highest burden of hepatitis C in the world, provides treatment through its National Control Strategy. Addressing the burden of viral hepatitis in the Balkan and Mediterranean regions will require national commitments in the form of strategic plans, financial and human resources, normative guidance and technical support from regional agencies and research. © 2013 John Wiley & Sons Ltd. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84879953822&partnerID=40&md5=646ef58402095788fdc931b03c07a70d | |
dc.subject | Balkan region | en |
dc.subject | hepatitis B | en |
dc.subject | hepatitis C | en |
dc.subject | hepatocellular carcinoma | en |
dc.subject | Mediterranean | en |
dc.subject | northern Africa | en |
dc.subject | surveillance | en |
dc.subject | adefovir | en |
dc.subject | boceprevir | en |
dc.subject | entecavir | en |
dc.subject | hepatitis B surface antigen | en |
dc.subject | hepatitis B(e) antigen | en |
dc.subject | interferon | en |
dc.subject | lamivudine | en |
dc.subject | peginterferon alpha2a | en |
dc.subject | ribavirin | en |
dc.subject | telaprevir | en |
dc.subject | telbivudine | en |
dc.subject | tenofovir | en |
dc.subject | virus vaccine | en |
dc.subject | aging | en |
dc.subject | awareness | en |
dc.subject | Balkan Peninsula | en |
dc.subject | blood donor | en |
dc.subject | blood safety | en |
dc.subject | blood transfusion | en |
dc.subject | chronic liver disease | en |
dc.subject | conference paper | en |
dc.subject | cost effectiveness analysis | en |
dc.subject | drug cost | en |
dc.subject | drug use | en |
dc.subject | harm reduction | en |
dc.subject | health care access | en |
dc.subject | health care personnel | en |
dc.subject | Hepatitis B virus | en |
dc.subject | Hepatitis C virus | en |
dc.subject | Hepatitis delta virus | en |
dc.subject | high risk population | en |
dc.subject | human | en |
dc.subject | infection control | en |
dc.subject | meta analysis (topic) | en |
dc.subject | migration | en |
dc.subject | morbidity | en |
dc.subject | mortality | en |
dc.subject | opiate substitution treatment | en |
dc.subject | outcome assessment | en |
dc.subject | practice guideline | en |
dc.subject | prevalence | en |
dc.subject | priority journal | en |
dc.subject | public health problem | en |
dc.subject | seroprevalence | en |
dc.subject | sexual intercourse | en |
dc.subject | sexually transmitted disease | en |
dc.subject | Southern Europe | en |
dc.subject | systematic review (topic) | en |
dc.subject | treatment duration | en |
dc.subject | vaccination | en |
dc.subject | virus transmission | en |
dc.subject | world health organization | en |
dc.subject | Antiviral Agents | en |
dc.subject | Carcinoma, Hepatocellular | en |
dc.subject | Cross Infection | en |
dc.subject | Disease Transmission, Infectious | en |
dc.subject | Epidemiological Monitoring | en |
dc.subject | Hepatitis B Vaccines | en |
dc.subject | Hepatitis B, Chronic | en |
dc.subject | Hepatitis C, Chronic | en |
dc.subject | Humans | en |
dc.subject | Liver Neoplasms | en |
dc.subject | Mediterranean Region | en |
dc.subject | Treatment Outcome | en |
dc.title | The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference | en |
dc.type | journalArticle | en |